Chargement en cours...
Concordance of KRAS/BRAF Mutation Status in Metastatic Colorectal Cancer before and after Anti-EGFR Therapy
Anti-EGFR targeted therapy is a potent strategy in the treatment of metastatic colorectal cancer (mCRC) but activating mutations in the KRAS gene are associated with poor response to this treatment. Therefore, KRAS mutation analysis is employed in the selection of patients for EGFR-targeted therapy...
Enregistré dans:
| Auteurs principaux: | , , , , , , , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Hindawi Publishing Corporation
2009
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2837901/ https://ncbi.nlm.nih.gov/pubmed/20300583 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2009/831626 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|